20/20 Biolabs, Inc. - Common Stock (NQ:AIDX)

0.8669 UNCHANGED

Streaming Delayed Price Updated: 3:59 PM EDT, May 29, 2026 Add to My Watchlist

Price and Volume

Volume	289,821
Open	-
Bid (Size)	0.8403 (1,100)
Ask (Size)	0.9700 (6,000)
Prev. Close	-
Today's Range	0.8300 - 0.9726
52wk Range	0.8300 - 50.00
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

20/20 Biolabs' Multi-Cancer Early Detection Blood Test Selected by State of Vermont to Screen up to 4,500 Firefighters

May 27, 2026

From 20/20 Biolabs Inc.

Via GlobeNewswire

20/20 Biolabs Commences Emergency Planning for Ebola & Hantavirus Lab Testing if Outbreak Creates Overflow Demand

May 22, 2026

From 20/20 Biolabs Inc.

Via GlobeNewswire

Performance

YTD	-96.4%	-96.4%
1 Month	-44.1%	-44.1%
3 Month	-77.3%	-77.3%
6 Month	-96.4%	-96.4%
1 Year	-96.4%	-96.4%

More News

20/20 BioLabs Reports First Quarter 2026 Financial Results and Recent Operational Progress

May 20, 2026

From 20/20 Biolabs Inc.

Via GlobeNewswire

20/20 BioLabs Exclusively Licenses PSA Velocity Algorithm from the University of South Carolina

May 12, 2026

From 20/20 Biolabs Inc.

Via GlobeNewswire

BIO-key International, 20/20 Biolabs, Society Pass, and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

April 10, 2026

Via ACCESS Newswire

20/20 BioLabs Selected by Evexia Diagnostics to Offer OneTest™ for Cancer Through Evexia Platform

April 07, 2026

From 20/20 Biolabs Inc.

Via GlobeNewswire

20/20 BioLabs Reports Full Year 2025 Financial Results and Recent Operational Progress

March 31, 2026

From 20/20 Biolabs Inc.

Via GlobeNewswire

Maryland Fire Departments Awarded $520,000 for Cancer Screenings using 20/20 BioLabs’ OneTest ™ Multi-Cancer Early Detection Blood Test

March 27, 2026

From 20/20 Biolabs Inc.

Via GlobeNewswire

What's Going On With 20/20 Biolabs Stock? ↗

March 24, 2026

Via Benzinga

20/20 BioLabs Announces Exclusive U.S. License Agreement with ROKIT Healthcare to Integrate Advanced CKD Prediction Technology into Its Longevity Test Program

March 24, 2026

From 20/20 Biolabs Inc.

Via GlobeNewswire

20/20 BioLabs Highlights Advantages of its Patented Protein Biomarker Technology for Multi-Cancer Early Detection in Light of Recent Studies

March 12, 2026

From 20/20 Biolabs Inc.

Via GlobeNewswire

20/20 BioLabs Launches OneTest for Longevity Blood Test and Chronic Disease Risk Assessment and Management Solution Built with IBM AI Capabilities

February 25, 2026

From 20/20 Biolabs Inc.

Via GlobeNewswire

20/20 BioLabs to Host Virtual Investor Webinar on Thursday, February 26, 2026 at 2:00 p.m. Eastern Time

February 20, 2026

From 20/20 Biolabs Inc.

Via GlobeNewswire

Frequently Asked Questions

Is 20/20 Biolabs, Inc. - Common Stock publicly traded?

Yes, 20/20 Biolabs, Inc. - Common Stock is publicly traded.

What exchange does 20/20 Biolabs, Inc. - Common Stock trade on?

20/20 Biolabs, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for 20/20 Biolabs, Inc. - Common Stock?

The ticker symbol for 20/20 Biolabs, Inc. - Common Stock is AIDX on the Nasdaq Stock Market

What is the current price of 20/20 Biolabs, Inc. - Common Stock?

The current price of 20/20 Biolabs, Inc. - Common Stock is 0.8669

When was 20/20 Biolabs, Inc. - Common Stock last traded?

The last trade of 20/20 Biolabs, Inc. - Common Stock was at 05/29/26 03:59 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.